Retatrutide for weight loss: what the phase 2 data actually shows

What did @ahmadyasinmd actually say?

Dr. Yasin called retarutide "the strongest weight loss peptide in the market now" and described it as a "third generation" GLP medication targeting GLP-1, GIP, and glucagon receptors simultaneously. He said it combines "appetite suppression, increased energy expenditure and improved insulin sensitivity," mentioned starting doses around 0.5 mg weekly up to 12 mg weekly, and disclosed that he has personally tried it. He also correctly noted it is not FDA-approved and remains in phase 3 trials. The disclaimer at the end tells viewers not to buy or use any peptide without consulting a doctor.

That last part matters. The rest of the video walks a narrow line between education and promotion, and a few claims deserve closer scrutiny.

Does the science back this up?

Partially, yes. The mechanism description is largely accurate, but calling retarutide the strongest peptide "in the market" is both scientifically premature and legally problematic for a compound that isn't on any approved market.

The phase 2 trial published by Jastreboff et al. (2023, New England Journal of Medicine) is the primary evidence base here. In that 24-week randomized controlled trial, participants receiving 12 mg retarutide weekly lost an average of 17.5% of body weight, which is a genuinely impressive number. For context, semaglutide 2.4 mg (Wegovy) showed roughly 14.9% at 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM). That comparison is not straightforward though. Different trial durations, different populations, different endpoints. Dr. Yasin doesn't acknowledge any of that nuance.

The triple-receptor mechanism (GLP-1, GIP, glucagon) is real and well-documented in the literature. Glucagon receptor agonism is theorized to increase energy expenditure beyond what GLP-1 alone achieves, which is the scientific rationale behind retatrutide's development. The increased heart rate side effect he mentions is specifically tied to glucagon receptor activity and is supported by the Jastreboff 2023 data.

What did they get wrong (or right)?

The name is wrong throughout. He calls it "RateroTide" repeatedly. The correct name is retatrutide (sometimes spelled retarutide in early literature). Small thing, but this is a medical video with 155,000 views.

More seriously, calling it "the strongest weight loss peptide in the market now" is inaccurate on two counts. First, retatrutide is not on any market. It is an investigational compound in phase 3 trials. Second, "strongest" is not a defined clinical term. The phase 2 data is promising, but phase 3 results are not yet published, and efficacy comparisons across peptides require head-to-head trials that do not exist.

The dosing information (0.5 mg to 12 mg weekly) tracks with the Jastreboff 2023 protocol, so that specific detail is accurate. However, presenting a phase 2 dosing schedule to a general TikTok audience without emphasizing that this compound is not commercially available and should not be self-administered from gray-market sources is a significant omission.

What he got right: the three-receptor mechanism, the FDA approval status disclosure, the side effect profile including nausea, vomiting, increased heart rate, and injection site reactions, and the general framing that this is investigational. Credit where it is due.

What should you actually know?

Retatrutide is being developed by Eli Lilly and is currently in phase 3 trials. You cannot get an FDA-approved version of this compound anywhere. What you can find on peptide marketplaces is research-grade or gray-market material with no standardized manufacturing oversight, no clinical dosing guidance validated for individual use, and no regulatory accountability.

The phase 2 data is genuinely exciting to researchers. A 17.5% body weight reduction at 24 weeks would represent a meaningful advance over existing options. But phase 2 trials are not phase 3 trials. They are smaller, shorter, and optimized to find a signal, not to establish long-term safety. The cardiovascular signals from glucagon receptor agonism, specifically that increased heart rate Dr. Yasin mentions, are exactly the kind of finding that requires larger, longer trials to properly characterize.

If a provider is offering you retatrutide today as a clinical treatment, they are not prescribing an approved drug. They are administering a compound with phase 2 data only. That is a meaningful distinction that any patient deserves to understand before agreeing to treatment.